These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1346 related items for PubMed ID: 12236627

  • 1. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 2. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 3. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P, Soares CN, Cohen LS, Lyster AK, Fava M.
    Arch Womens Ment Health; 2004 Jul 30; 7(3):167-71. PubMed ID: 15241662
    [Abstract] [Full Text] [Related]

  • 4. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Jul 30; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 5. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R.
    Ann Clin Psychiatry; 2010 Aug 30; 22(3):166-71. PubMed ID: 20680189
    [Abstract] [Full Text] [Related]

  • 6. Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset.
    Ongur D, Farabaugh A, Iosifescu DV, Perlis R, Fava M.
    Psychother Psychosom; 2005 Aug 30; 74(3):173-8. PubMed ID: 15832068
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH, Salinas E.
    J Clin Psychiatry; 2001 Jul 30; 62(7):523-9. PubMed ID: 11488362
    [Abstract] [Full Text] [Related]

  • 8. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH, Ravindran A.
    J Clin Psychiatry; 1999 Jan 30; 60(1):22-8. PubMed ID: 10074873
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.
    J Clin Psychiatry; 1999 Sep 30; 60(9):580-3. PubMed ID: 10520975
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC.
    Encephale; 2010 Oct 30; 36(5):425-32. PubMed ID: 21035633
    [Abstract] [Full Text] [Related]

  • 11. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug 30; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 12. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B, Andersen HF, Dolberg OT.
    Depress Anxiety; 2007 Aug 30; 24(1):53-61. PubMed ID: 16937393
    [Abstract] [Full Text] [Related]

  • 13. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.
    Ann Clin Psychiatry; 2007 Aug 30; 19(1):5-8. PubMed ID: 17453655
    [Abstract] [Full Text] [Related]

  • 14. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE.
    Int Clin Psychopharmacol; 2005 Mar 30; 20(2):87-91. PubMed ID: 15729083
    [Abstract] [Full Text] [Related]

  • 15. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG.
    J Clin Psychiatry; 1991 Aug 30; 52(8):329-35. PubMed ID: 1907963
    [Abstract] [Full Text] [Related]

  • 16. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA, Schweizer E, Rickels K.
    J Clin Psychiatry; 1996 Jun 30; 57(6):245-8. PubMed ID: 8666561
    [Abstract] [Full Text] [Related]

  • 17. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M.
    J Clin Pharm Ther; 2005 Apr 30; 30(2):133-8. PubMed ID: 15811165
    [Abstract] [Full Text] [Related]

  • 18. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.
    J Ment Health Policy Econ; 2010 Mar 30; 13(1):27-35. PubMed ID: 20571180
    [Abstract] [Full Text] [Related]

  • 19. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A, Roose S.
    Am J Geriatr Psychiatry; 2006 Apr 30; 14(4):361-70. PubMed ID: 16582045
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
    Gao K, Muzina D, Gajwani P, Calabrese JR.
    J Clin Psychiatry; 2006 Sep 30; 67(9):1327-40. PubMed ID: 17017818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.